Q2042 Tisagenlecleucel car-pos t
Also known as: Kymriah, tisagenlecleucel, CAR-T
Tisagenlecleucel CAR-positive T-cell therapy, chimeric antigen receptor T-cell immunotherapy for CD19-positive hematologic malignancies.
In Plain Language
cancer cell fighter; engineered cell therapy
Clinical Context
Used for relapsed/refractory B-cell acute lymphoblastic leukemia in children and adults, and certain lymphomas. Engineered cells target CD19+ malignancies.
RVU Information
CPT Q2042 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q2042?
CPT Q2042 (Tisagenlecleucel car-pos t) is a Q Codes code. Tisagenlecleucel CAR-positive T-cell therapy, chimeric antigen receptor T-cell immunotherapy for CD19-positive hematologic malignancies.
Is Q2042 covered by insurance?
Q2042 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used for relapsed/refractory B-cell acute lymphoblastic leukemia in children and adults, and certain lymphomas. Engineered cells target CD19+ malignancies.
When is CPT Q2042 used?
Used for relapsed/refractory B-cell acute lymphoblastic leukemia in children and adults, and certain lymphomas. Engineered cells target CD19+ malignancies.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.